Ms. Howson is currently an Independent Director at MEI Pharma, Inc. and Cue Biopharma, Inc. Earlier, she was a Senior Advisor on the transaction team at JSB-Partners, providing business development support to life sciences companies. Before that, she served as Executive Vice President, Corporate Business Development at Lexicon Pharmaceuticals, Inc. Prior, Ms. Howson was Senior Vice President, Corporate and Business Development at Bristol-Myers Squibb Company, responsible for worldwide oversight and management of the identification, evaluation and negotiation of mergers and acquisitions, licensing and other external alliance activities. Additionally, Ms. Howson spent nearly a decade at SmithKline Beecham, where she served as Senior Vice President and Director, Business Development and managed the company’s USD 100 million venture capital fund, SR One.
During her career, Ms. Howson has also served on the boards of companies including Organovo Holdings, Inc., Actavis Pharma, Inc., ContraVir Pharmaceuticals, Inc., Cynapsus Therapeutics Inc., Enzymotec Ltd., Idenix Pharmaceuticals, Inc., IPM-International Partnership for Microbicides and OXiGENE, Inc.
Ms. Howson earned a Bachelor of Science in chemical engineering from the Technion – Israeli Institute of Technology, a Master of Science in chemical engineering from the City College of New York and a Master of Business Administration from Columbia University.
Ms. Howson has been a member of Immunic’s Board since October 2019. She is chairman of the Compensation Committee.